CN104910129A - Xanthate compounds containing hexamethyl benzene ring and halogeno-benzene, and preparation method and application thereof - Google Patents
Xanthate compounds containing hexamethyl benzene ring and halogeno-benzene, and preparation method and application thereof Download PDFInfo
- Publication number
- CN104910129A CN104910129A CN201510351838.XA CN201510351838A CN104910129A CN 104910129 A CN104910129 A CN 104910129A CN 201510351838 A CN201510351838 A CN 201510351838A CN 104910129 A CN104910129 A CN 104910129A
- Authority
- CN
- China
- Prior art keywords
- compound
- benzene
- preparation
- halogeno
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 C[C@](COc1cc(*)c(Cc2c(C)c(C)c(C)c(C)c2C)cc1)OC(SCc1ccc[s]1)=S Chemical compound C[C@](COc1cc(*)c(Cc2c(C)c(C)c(C)c(C)c2C)cc1)OC(SCc1ccc[s]1)=S 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/18—Radicals substituted by singly bound hetero atoms other than halogen by sulfur atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to the field of drugs related to Type 2 diabetes, particularly xanthate AMPK activators containing hexamethyl benzene ring and halogeno-benzene and a preparation method thereof, and application of the compounds in preparing drugs for Type 2 diabetes. In the formula, R is selected from C1-C3 alkyl groups.
Description
Technical field
The present invention relates to the pharmaceutical field of diabetes B treatment.More particularly, the present invention relates to the xanthate class AMPK activator, its preparation method that the medicative class of diabetes B tool are contained to hexamethyl phenyl ring and halogeno-benzene structure, and the purposes in pharmacy.
Background technology
Diabetes are the lysis caused by multi-pathogenesis, have influence on the population in the whole world 6%.Expect 2025, number of patients can double again and reach 300,000,000.The most important clinical pathologic characteristic of diabetes is that plasma glucose (blood sugar) concentration increases.It is the major cause leading diabetogenic various clinical symptom that blood sugar concentration increases.Unsteered hyperglycemia causes many diabetic complications, as increased capillary blood vessel and macrovascular diseases risk, comprises ephrosis, neuropathy, retinopathy, hypertension, cerebral ischemia and coronary heart disease etc.Therefore, the key that blood sugar is treatment and prevent diabetes and complication thereof is reduced.
The protein kinase (AMPK) that AMP (adenylic acid) activates participates in multiple metabolic process as a kind of important protein kinase.AMPK plays master switch effect in the balance of adjuster body energy metabolism.In muscle and liver, the activation of AMPK enhances the picked-up of glucose, fatty acid oxidation and insulin sensitivity, and decreases the generation of glucose, cholesterol and triglyceride level.Therefore, AMPK and signal path thereof are diabetes B active drug action target spots.In fact, the biguanides of widespread use clinically at present, controlling as N1,N1-Dimethylbiguanide, phenformin and buformin is exactly AMPK activator.Wherein N1,N1-Dimethylbiguanide is a current most widely used line antidiabetic medicine clinically, be not only first-selected Remedies for diabetes and also on euglycemia without impact.This shows that AMPK is the keying action target spot of type ii diabetes pharmacological agent.But a severe side effect of these widely used biguanides AMPK activator clinically to cause lactic acidosis at present.Lactic acidosis is the metabolism class disease that a class is serious, once occur threat to life.Just because of causing lactic acidosis, the biguanides AMPK activator such as phenformin are terminated clinical application in states such as America and Europes.Although N1,N1-Dimethylbiguanide causes the probability of lactic acidosis, comparatively phenformin is low, but in oral antidiabetic drug, it causes serious toxic side effects and causes dead clinical report number maximum, therefore, research and develop novel, non-biguanides AMPK activator to have and important clinical meaning as the medicine of diabetes.
The invention discloses the xanthate class AMPK activator that a class contains hexamethyl phenyl ring and halogeno-benzene structure, these compounds can be used for the medicine preparing treatment diabetes B.
Summary of the invention
An object of the present invention is to provide a kind of AMPK agonist with the excellent activity of general formula I.
Another object of the present invention is to provide the method that preparation has the compound of general formula I.
The compound that another object of the present invention is to provide containing general formula I is treating the application in diabetes B as effective constituent.
Now in conjunction with object of the present invention, content of the present invention is specifically described.
The compound that the present invention has general formula I has following structural formula:
Wherein, R is selected from halogenic substituent.
The compound of preferred formula I has following structure,
Compound of Formula I of the present invention is synthesized by following route:
Compound II per reacts with compound III under Louis acid catalysis, obtains compound IV; Compound IV is through BX
3process the methyl sloughed on methoxyl group, obtain VI; Compound VI by first in the presence of a base with CS
2reaction, obtains corresponding wasteland hydrochlorate, the latter again with after the compound VI I that adds there is substitution reaction, obtain Compound I; Wherein, the definition of X=Br or Cl, R as previously mentioned.
Compound of Formula I of the present invention has AMPK activation, can be used as effective constituent for the preparation of diabetes B medicine.The activity of compound of Formula I of the present invention is verified by receptor binding assays.
Compound of Formula I of the present invention is effective in quite wide dosage range.The dosage that such as every day takes, within the scope of 1mg-1000mg/ people, is divided into once or administration for several times.The actual dosage taking compound of Formula I of the present invention can be decided according to relevant situation by doctor.
Embodiment
Below in conjunction with embodiment, the present invention is further illustrated.It should be noted that, following embodiment be only for illustration of, and not for limiting the present invention.The various changes that those skilled in the art's training centre according to the present invention is made all should within the protection domain required by the application's claim.
the synthesis of embodiment 1 Compound I-1
A. the synthesis of compound IV-1
Compound II per (1.48g, 10mmol) and compound III-1 (1.91g, 10mmol) are dissolved in the CH of 20mL drying
2cl
2in, stirred at ambient temperature, adds anhydrous AlCl
3(1.33g, 10mmol), then reaction mixture at room temperature stirs and spends the night, and TLC shows reaction to be completed.Reaction mixture pours in 200mL frozen water, stirs, uses CH
2cl
2(60mL × 3) extract, and merge extraction phase, use 1% dilute hydrochloric acid and salt water washing successively, anhydrous sodium sulfate drying.Suction filtration removing siccative, filtrate is evaporate to dryness on a rotary evaporator, and the resistates obtained uses column chromatography purification, obtains compound IV-1, white solid.ESI-MS,m/z＝303([M+H]
+)。
B. the synthesis of compound V-1
Compound IV-1 (1.81g, 6mmol) is dissolved in the CH of 15mL drying
2cl
2in, be cooled to-50 DEG C under nitrogen protection, stir, slowly drip the BCl of 1.0M with syringe
3the CH of (10mL, 10mmol)
2cl
2solution, after dropwising, reaction mixture is warmed up to room temperature gradually, and at room temperature stirs 1 hour, and TLC shows reaction to be completed.Reaction mixture pours in 200mL frozen water, stirs, uses CH
2cl
2(60mL × 3) extract, and merge extraction phase, use salt water washing, anhydrous sodium sulfate drying.Suction filtration removing siccative, filtrate is evaporate to dryness on a rotary evaporator, and the resistates obtained uses column chromatography purification, obtains compound V-1, white solid.ESI-MS,m/z＝289([M+H]
+)。
The synthesis of C.VI-1
Compound V-1 (1.15g, 4mmol) be dissolved in 10mL THF, stirred at ambient temperature, add NaOH (0.40g, 10mmol), stirred at ambient temperature 30 minutes, then add (R)-propylene oxide (0.29g, 5mmol), gained reaction mixture then temperature rising reflux 12 hours, TLC shows reaction to be completed.Reaction mixture pours in 100mL frozen water, stirs, uses CH
2cl
2(60mL × 3) extract, and merge extraction phase, use salt water washing, anhydrous sodium sulfate drying.Suction filtration removing siccative, filtrate is evaporate to dryness on a rotary evaporator, and the resistates obtained uses column chromatography purification, obtains compound VI-1, white solid.ESI-MS,m/z＝347([M+H]
+)。
D. the synthesis of Compound I-1
Compound VI-1 (0.69g, 2mmol) is dissolved in the THF of 10mL drying, and stirred at ambient temperature adds 60%NaH (0.40g, 10mmol), continues stirring 30 minutes, then adds dry CS
2(0.23g, 3mmol), continue stirring 30 minutes, finally add compound VI I-1 (0.40g, 3mmol), reaction mixture at room temperature stirs 5 hours, and TLC follows the tracks of and finds that reaction completes.Reaction mixture pours in 100mL frozen water, stirs, uses CH
2cl
2(60mL × 3) extract, and merge extraction phase, use salt water washing, anhydrous sodium sulfate drying.Suction filtration removing siccative, filtrate is evaporate to dryness on a rotary evaporator, and the resistates obtained uses column chromatography purification, obtains Compound I-1, white solid.ESI-MS,m/z＝520([M+H]
+)。
embodiment 2-4
With reference to embodiment 1 operation steps, synthesize compound listed in Table.
embodiment 5 Compound ira vitro is to the activation of AMPK
To recombinate AMPK enzyme reactivating with LKBl in vitro before enzyme assay expression in escherichia coli people.Use two kinds of technology for detection AMPK enzymic activitys based on fluorescence (α-screening and Delfia) and (comprise 25mM Tris/HCl damping fluid, pH7.5, Hepes damping fluid containing 100 μMs of ATP/50mM respectively at microwell plate, 25mM Tris/HCl damping fluid, pH7.4, containing 125 μMs of ATP) on synthesis skin substrate (AMARAASAAALARRR, i.e. " AMARAA " skin) and serial dilution activator existence under carry out.By adding AMPK (50-100ng) initiation reaction.After mixing, plank is at room temperature hatched 30 minutes.Enzymic activity is detected to measure the phosphoric acid amount of mixing in AMARAA by using the antibody of anti-phosphorylate serine.Activity represents with the percentage (%) contrasting (Basal activity is expressed as 100).
Test result sees the following form.
| Compound | α-screening | Delfia |
| Compound I-1 | 217 | 185 |
| Compound I-2 | 161 | 183 |
| Compound I-3 | 196 | 206 |
| Compound I-4 | 144 | 172 |
As can be seen from upper table result, compound of the present invention has very strong activation to AMPK, can as preparation treatment diabetes B medicine.
Claims (4)
1. there is the compound of general formula I,
Wherein, R is selected from halogenic substituent.
2. the compound of Formula I that defines of claim 1, is selected from following compounds,
3. synthesize arbitrary the defined method belonging to the compound of general formula (I) of claim 1-2:
Compound II per reacts with compound III under Louis acid catalysis, obtains compound IV; Compound IV is through BX
3process the methyl sloughed on methoxyl group, obtain VI; Compound VI by first in the presence of a base with CS
2reaction, obtains corresponding wasteland hydrochlorate, the latter again with after the compound VI I that adds there is substitution reaction, obtain Compound I; Wherein, the definition of X=Br or Cl, R as arbitrary in claim 1-2 as described in.
4. the compound of Formula I that one of claim 1-2 defines is preparing the application in treatment diabetes B medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510351838.XA CN104910129A (en) | 2015-06-23 | 2015-06-23 | Xanthate compounds containing hexamethyl benzene ring and halogeno-benzene, and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510351838.XA CN104910129A (en) | 2015-06-23 | 2015-06-23 | Xanthate compounds containing hexamethyl benzene ring and halogeno-benzene, and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104910129A true CN104910129A (en) | 2015-09-16 |
Family
ID=54079627
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510351838.XA Pending CN104910129A (en) | 2015-06-23 | 2015-06-23 | Xanthate compounds containing hexamethyl benzene ring and halogeno-benzene, and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104910129A (en) |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2853505A (en) * | 1957-10-17 | 1958-09-23 | Monsanto Chemicals | Halogen substituted alkenyl xanthates |
| DE2149246A1 (en) * | 1971-10-02 | 1973-04-05 | Riedel De Haen Ag | 2-phenoxyethanol xanthates and thiocarbamates - with virustatic activity |
| US3965137A (en) * | 1974-05-02 | 1976-06-22 | Stauffer Chemical Company | Thiocyano xanthates |
| JPS5330696B1 (en) * | 1970-11-10 | 1978-08-29 | ||
| CN85105807A (en) * | 1984-07-18 | 1987-01-28 | 山道士有限公司 | The preparation method of novel aromatic compounds |
| US5037991A (en) * | 1984-07-18 | 1991-08-06 | Sandoz Ltd. | Novel substituted aromatic compounds |
| CN104395319A (en) * | 2012-06-29 | 2015-03-04 | 普克塞尔公司 | Thienopyridone derivatives useful as activators of ampk |
-
2015
- 2015-06-23 CN CN201510351838.XA patent/CN104910129A/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2853505A (en) * | 1957-10-17 | 1958-09-23 | Monsanto Chemicals | Halogen substituted alkenyl xanthates |
| JPS5330696B1 (en) * | 1970-11-10 | 1978-08-29 | ||
| DE2149246A1 (en) * | 1971-10-02 | 1973-04-05 | Riedel De Haen Ag | 2-phenoxyethanol xanthates and thiocarbamates - with virustatic activity |
| US3965137A (en) * | 1974-05-02 | 1976-06-22 | Stauffer Chemical Company | Thiocyano xanthates |
| CN85105807A (en) * | 1984-07-18 | 1987-01-28 | 山道士有限公司 | The preparation method of novel aromatic compounds |
| US5037991A (en) * | 1984-07-18 | 1991-08-06 | Sandoz Ltd. | Novel substituted aromatic compounds |
| CN104395319A (en) * | 2012-06-29 | 2015-03-04 | 普克塞尔公司 | Thienopyridone derivatives useful as activators of ampk |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2019001383A1 (en) | N-benzenesulfonylbenzamide compound for inhibiting bcl-2 protein and composition and use thereof | |
| US20150353528A1 (en) | Optically active pyrazolylaminoquinazoline, and pharmaceutical compositions and methods of use thereof | |
| CN107162921A (en) | The new Phenoxiacetic acid derivatives of one class, its preparation method and its purposes as medicine | |
| CN104910129A (en) | Xanthate compounds containing hexamethyl benzene ring and halogeno-benzene, and preparation method and application thereof | |
| CN108350007A (en) | A kind of substituted adenine compound and its pharmaceutical composition | |
| CN105037322A (en) | Xanthate compounds containing hexamethylbenzene ring and alkoxyl benzene structures, as well as preparation methods and application thereof | |
| CN105037321A (en) | Xanthate AMPK activating agents comprising hexamethylbenzene ring structures, as well as preparation methods and application thereof | |
| CN104892569A (en) | Terminal-substituted nitrobenzene hexamethylbenzene xanthate compound, preparation method and application | |
| CN104945370A (en) | Xanthate compound containing halothiophene and nitrobenzene hexamethylbenzene structure, preparation method and application | |
| CN104945369A (en) | Xanthic acid ester compound containing hexamethyl benzene ring and nitrobenzene structures and preparation method and application thereof | |
| CN105001194A (en) | Xanthate compound containing aminothiophene and hexamethylbenzene structures, and preparation method and application thereof | |
| CN104945371A (en) | Xanthate ester compound containing nitrile thiophene and with hexamethylbenzene structure and preparation method and application thereof | |
| CN104945431B (en) | A kind of preparation method of the schiff bases vanadyl complex crystal for having biological activity | |
| CN104892568A (en) | Xanthate ester compound containing haxamethyl benzene ring and nitrile group benzene structure and preparation method and application of xanthate ester compound | |
| CN104910130A (en) | Xanthate compound containing hexamethylbenzene ring and aminobenzene structures as well as preparation method and application thereof | |
| CN104945372A (en) | Dinitrosalicylic xanthate ester compound with hexamethylbenzene structure and preparation method and application thereof | |
| CN115385819A (en) | Rosmarinic acid bioelectronic isostere and preparation method and application thereof | |
| JP2021508319A (en) | Salt form as an Akt inhibitor and its crystal form | |
| CN105622452A (en) | AHU-377 crystal-type free acid, preparation method and applications thereof | |
| CN1583747A (en) | Pterin mononitrogen monoxide synthase inhibitor | |
| CN110903292B (en) | Multi-target inhibitor acting on QC and GSK-3 beta | |
| CN104926757A (en) | Diacyl benzylamine AMPK activator containing alcoxyl phenyl group, and preparation method and purpose of diacyl benzylamine AMPK activator | |
| CN104926756A (en) | Di-acyl benzylamine compound with cyano benzene, method for manufacturing di-acyl benzylamine compound and application thereof | |
| CN104926755A (en) | Nitrobenzene di-acyl benzylamine AMPK (adenosine monophosphate activated protein kinase) activator, method for manufacturing same and application of nitrobenzene di-acyl benzylamine AMPK activator | |
| CN105001181A (en) | Bisacyl benzylamine AMPK activator, and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20150916 |